Utilization of methylnaltrexone (relistor) for opioid-induced constipation in an oncology hospital
Recent federal programs may expand access and lower GLP-1 costs in the near future
Back to Journals Drug Design, Development and Therapy Volume 20 Fibroblast Growth Factor 21: Mechanisms, Therapeutic Potential, and Clinical Translation in Metabolic Dysfunction Authors Rama K, Jahagirdar V, Sanyal AJ Received 26 December 2025 Accepted for publication 13 April 2026 Published 28 April 2026 Volume 2026:20 560034 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Professor Mariana Carmen Chifiriuc Kaanthi Rama, * Vinay Jahagirdar, * Arun J Sanyal Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA *These authors contributed equally to this work Correspondence: Arun J Sanyal, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, MCV Box 980342, Richmond, VA, 23298-0342, USA, Tel +1-804 828 6314, Email [email protected] Abstract: Fibroblast growth factor 21 (FGF21) is an endocrine hepatokine that coordinates systemic energy metabolism by linking hepatic nutrient sensing with adipose and central signalling pathways
If you want to see whether a personalized plan fits your goals, you can take our free assessment quiz
